Cat. No. 1396
Alternative Name: 4-HPR
Chemical Name: N-(4-Hydroxyphenyl)retinamide
Biological ActivitySynthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Le Doze et al (2000) Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of rat. Drug Metab.Dispos. 28 205. PMID: 10640519.
Takahashi (2000) Antioxidant properties of N-(4-hydroxyphenyl)retinamide (fenretinide). Biol.Pharm.Bull. 23 222. PMID: 10706389.
Ulukaya and Wood (1999) Fenretinide and its relation to cancer. Cancer Treat.Rev. 25 229. PMID: 10448131.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Fenretinide include:
Seidensaal et al (2015) Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma. Am J Pathol 14 204. PMID: 26634247.
Johansson et al (2013) Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun 4 2175. PMID: 23868472.
Do you know of a great paper that uses Fenretinide from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Fenretinide, supplier, Synthetic, retinoid, agonists, Potent, anti-cancer, agent, RXR, Retinoid, X, Receptors, RAR, RAMBA, Retinoic, Acid, Tocris Bioscience, Retinoic Acid Receptor products